Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Revolution Medicines, Inc. RVMD NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
45/100
1/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$124.36
-15.4%

Revolution Medicines, Inc. (RVMD) is a Biotechnology company in the Healthcare sector, currently trading at $147.01. It has a SharesGrow Score of 43/100, indicating a mixed investment profile with 1 out of 7 criteria passed.

Analyst consensus target is RVMD = $124 (-15.4% upside).

Valuation: RVMD trades at a trailing Price-to-Earnings (P/E) of -16.3 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 1.31.

Net income is $1.1B (loss), growing at -67.2%/yr. Net profit margin is 0% (thin). Gross margin is 100% (+27.3 pp trend).

Balance sheet: total debt is $159M against $1.6B equity (Debt-to-Equity (D/E) ratio 0.1, conservative). Current ratio is 7.14 (strong liquidity). Debt-to-assets is 6.7%. Total assets: $2.4B.

Analyst outlook: 19 / 20 analysts rate RVMD as buy (95%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 53/100 (Partial), Growth 15/100 (Fail), Past 0/100 (Fail), Health 67/100 (Partial), Moat 68/100 (Partial), Future 64/100 (Pass), Income ?/100 (Fail).

$124.36
▼ 15.41% Downside
Average Price Target
Based on 20 Wall Street analysts offering 12-month price targets for Revolution Medicines, Inc., the average price target is $124.36, with a high forecast of $170.00, and a low forecast of $73.00.
Highest Price Target
$170.00
Average Price Target
$124.36
Lowest Price Target
$73.00

RVMD SharesGrow Score Overview

53/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 53/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 68/100
Gross margin is + market cap
FUTURE 64/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — RVMD

~
VALUE Partial
53/100
RVMD trades at a trailing Price-to-Earnings (P/E) of -16.3 (S&P 500 average ~25). Forward PEG 1.31 — ~moderate (~1.5). Trailing PEG 1.09. Analyst consensus target is $124, implying -15.7% from the current price $147. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
RVMD: -83.6%/yr revenue is, -67.2%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
67/100
Balance sheet RVMD: Debt-to-Equity (D/E) ratio 0.1 (conservative), Current ratio is 7.14 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
68/100
RVMD: Gross margin is 100% (+27.3 pp trend), $29B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 68/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
64/100
Analyst outlook: 19 / 20 analysts rate RVMD as buy (95%). Analyst consensus target is $124 (-15.7% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range29.17-124.49
Volume7.88M
Avg Volume (30D)3.05M
Market Cap$29.13B
Beta (1Y)1.01
Share Statistics
EPS (TTM)-5.95
Shares Outstanding$190.13M
IPO Date2020-02-13
Employees616
CEOMark A. Goldsmith
Financial Highlights & Ratios
Gross Profit$-16.56M
EBITDA$-1.09B
Net Income$-1.13B
Operating Income$-1.18B
Total Cash$2.03B
Total Debt$158.7M
Net Debt$-225.04M
Total Assets$2.35B
Price / Earnings (P/E)-24.7
Analyst Forecast
1Y Price Target$143.00
Target High$170.00
Target Low$73.00
Upside-2.7%
Rating ConsensusBuy
Analysts Covering20
Buy 95% Hold 5% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS76155X1000

Price Chart

Track all markets on TradingView
RVMD
Revolution Medicines, Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
29.17 52WK RANGE 124.49

People Also View

BPMC
BPMC
Blueprint Medicines Corporation
$129.46
+0.14%
 KYMR
KYMR
Kymera Therapeutics, Inc.
$89.87
+1.51%
 PTGX
PTGX
Protagonist Therapeutics, Inc.
$104.72
+7.33%
 AKRO
AKRO
Akero Therapeutics, Inc.
$54.65
+0.00%
 STOK
STOK
Stoke Therapeutics, Inc.
$35.86
+2.31%
 AGIO
AGIO
Agios Pharmaceuticals, Inc.
$33.30
+0.45%
 NRIX
NRIX
Nurix Therapeutics, Inc.
$16.30
+2.45%
 GLUE
GLUE
Monte Rosa Therapeutics, Inc.
$17.50
-0.28%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message